Share on StockTwits

Cytomedix (NASDAQ:CMXI) released its earnings data on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01, AnalystRatings.NET reports.

On a related note, analysts at Zacks upgraded shares of Cytomedix from a “hold” rating to a “buy” rating in a research note on Thursday, April 24th.

Cytomedix (NASDAQ:CMXI) opened at 0.40 on Thursday. Cytomedix has a 1-year low of $0.33 and a 1-year high of $0.68. The stock has a 50-day moving average of $0.53 and a 200-day moving average of $0.5. The company’s market cap is $48.5 million.

Cytomedix, Inc is a United States-based company that develops biologically active regenerative therapies for wound and tissue repair.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.